Aspirin Labeling Should Reflect Risk-Based CVD Prevention, Bayer Says
This article was originally published in The Tan Sheet
Executive Summary
Aspirin therapy labeling should be revised to include an indication for primary prevention of myocardial infarction, reflecting a risk-based approach to cardiovascular disease prevention, Bayer maintains in a recent submission to FDA